<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866840</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000637646</org_study_id>
    <secondary_id>P30CA072720</secondary_id>
    <secondary_id>CINJ-090802</secondary_id>
    <nct_id>NCT00866840</nct_id>
  </id_info>
  <brief_title>Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Phase II Trial of Riluzole in Patients With Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective&#xD;
      treatment for melanoma.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well riluzole works in treating patients with&#xD;
      stage III or stage IV melanoma that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine whether administration of a daily dose of riluzole results in tumor shrinkage,&#xD;
           as measured by RECIST criteria, in patients with advanced melanoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the long-term toxicity of riluzole when administered to these patients.&#xD;
&#xD;
        -  Compare the survival of these patients with historical controls.&#xD;
&#xD;
      OUTLINE: Patients receive oral riluzole twice daily on days 1-28. Courses repeat every 28&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor shrinkage, as measured by RECIST criteria</measure>
    <time_frame>Treatment start date to date of best response</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term toxicity of riluzole, as measured by NCI CTCAE version 3.0</measure>
    <time_frame>Treatment start date through follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Treatment start date to date of death</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>riluzole</intervention_name>
    <description>100 mg orally twice daily</description>
    <arm_group_label>Riluzole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant melanoma&#xD;
&#xD;
               -  Unresectable stage III or stage IV disease&#xD;
&#xD;
          -  Measurable disease according to RECIST criteria, defined as ≥ 1 unidimensionally&#xD;
             measurable lesion &gt; 20 mm by conventional techniques or &gt; 10 mm by spiral CT scan&#xD;
&#xD;
          -  No known brain metastases unless treated and stable for ≥ 2 weeks by MRI evaluation&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,000/μL&#xD;
&#xD;
          -  Platelet count ≥ 50,000/μL&#xD;
&#xD;
          -  Total bilirubin ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT ≤ 3 times ULN&#xD;
&#xD;
          -  INR ≤ 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 weeks after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No second primary malignancy, except carcinoma in situ of the cervix, adequately&#xD;
             treated nonmelanoma carcinoma of the skin, or other malignancy treated ≥ 5 years ago&#xD;
             with no evidence of recurrence&#xD;
&#xD;
          -  No concurrent serious systemic disorders (including active infections) that, in the&#xD;
             opinion of the investigator, would compromise the safety of the patient or compromise&#xD;
             the patient's ability to complete the study&#xD;
&#xD;
          -  No history of allergic reactions attributed to riluzole&#xD;
&#xD;
          -  No known history of hepatitis B or C&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No more than 1 prior therapeutic chemotherapy regimen for advanced melanoma&#xD;
&#xD;
          -  Prior treatment with riluzole on clinical trial CINJ-090603 allowed&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for the&#xD;
             treatment of the malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James S. Goydos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>March 20, 2009</study_first_submitted>
  <study_first_submitted_qc>March 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2009</study_first_posted>
  <last_update_submitted>November 18, 2013</last_update_submitted>
  <last_update_submitted_qc>November 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 6, 2017</submitted>
    <returned>April 18, 2017</returned>
    <submitted>February 11, 2021</submitted>
    <returned>March 3, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

